Cognition Therapeutics to Present Proteomic Biomarker Analyses from Clinical Studies of CT1812 in Patients with Alzheimer’s Disease at AD/PD 2023

Rhea-AI Summary

Cognition Therapeutics, Inc. (NASDAQ: CGTX) will present results from a proteomic biomarker meta-analysis of cerebrospinal fluid samples from participants in their Phase 2 SHINE and Phase 1b SPARC studies, focusing on mild-to-moderate Alzheimer's disease. The analysis identified biomarkers of CT1812 activity, which inform the understanding of Alzheimer's progression. A poster presentation is scheduled at the AD/PD™ 2023 conference in Gothenburg, Sweden, from March 28 to April 1, 2023. Additionally, CEO Lisa Ricciardi will participate in a panel on innovative approaches to Alzheimer's research on March 29, emphasizing the importance of rigorous clinical trials.

Positive

• Identification of biomarkers for CT1812 activity across two studies indicates potential efficacy.
• CT1812's mechanism targets key processes impaired in Alzheimer's disease, differentiating it from existing therapies.

Negative

• None.

- CEO Participating on Panel Hosted by Alzheimer’s Drug Discovery Foundation -

NEW YORK, March 21, 2023 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ: CGTX) will be presenting results of a proteomic biomarker meta-analysis of cerebrospinal fluid, or CSF, samples from the initial cohort of participants in the Phase 2 SHINE (COG0201; NCT03507790) and Phase 1b SPARC (COG0105; NCT03493282) studies with mild-to-moderate Alzheimer's disease who were treated with either CT1812 or placebo. Results of this analysis identified biomarkers of CT1812 activity that replicated across these two independent studies and patient cohorts. These findings inform our understanding of the impact of CT1812 treatment on the network of biologic pathways associated with Alzheimer’s disease progression. A detailed poster presentation (poster #P0407) will be made at the upcoming AD/PD™ 2023: the International Conference on Alzheimer’s & Parkinson’s Diseases being held in Gothenburg, Sweden from March 28 to April 1, 2023.

In addition, Lisa Ricciardi, CEO of Cognition Therapeutics will be participating in a panel hosted by the Alzheimer’s Drug Discovery Foundation. The panel, “Emerging Solutions: Novel Approaches to Alzheimer’s Disease” will take place in the Industry Symposium, “Building the Future: Novel Approaches and Innovations in Alzheimer’s Research" being held on March 29, 2023 at 11:40am local time. The panelists will discuss the need for multiple novel approaches to address neurodegenerative diseases with an emphasis on the value of rigorous and biomarker-driven clinical trials to help implement this multipronged approach.

Poster details:
Title: Pharmacodynamic Effects of the S2R Modulator CT1812 in Alzheimer’s Disease (AD) Patients Observed in a Meta-analysis of CSF Proteomes from SPARC and SHINE Part A
Authors: Duong D, Waybright L, Pandey K, Lizama B, Mecca A, van Dyck C, Grundman M, Blennow K, Zetterberg H, Caggiano AO, Seyfried N, Hamby ME
Date/Time:   March 29, 2023 – April 1, 2023

About CT1812
CT1812 is an experimental orally delivered small molecule designed to penetrate the blood-brain barrier and bind selectively to the sigma-2 (σ-2) receptor complex. The σ-2 receptor complex is involved in the regulation of key cellular processes such as membrane trafficking and autophagy that are damaged by toxic interaction with soluble beta amyloid (Aβ) oligomers, oxidative stress and other stressors. This damage to sensitive synapses can progress to a loss of synaptic function, which manifests as cognitive impairment and Alzheimer’s disease progression. CT1812 is currently in development for mild-to-moderate Alzheimer’s disease in the SHINE study (NCT03507790) and dementia with Lewy bodies in the SHIMMER study (NCT05225415).

About Cognition Therapeutics, Inc.
Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative disorders of the central nervous system and retina. We are currently investigating our lead candidate CT1812 in clinical programs in Alzheimer’s disease, dementia with Lewy bodies (DLB) and dry age-related macular degeneration (dry AMD). We believe CT1812 and our pipeline of σ-2 receptor modulators can regulate pathways that are impaired in these diseases. We believe that targeting the σ-2 receptor with CT1812 represents a mechanism functionally distinct from other current approaches in clinical development for the treatment of degenerative diseases. More about Cognition Therapeutics and its pipeline can be found at http://cogrx.com.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. All statements contained in this press release, other than statements of historical facts or statements that relate to present facts or current conditions, including but not limited to, statements regarding our product candidates, any expected or implied benefits or results, including that initial clinical results observed with respect to CT1812 will be replicated in later trials and our clinical development plans, including statements regarding our Phase 2 START study of CT1812, are forward-looking statements. These statements, including statements relating to the timing and expected results of our clinical trials, and cash runway, involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” might,” “will,” “should,” “expect,” “plan,” “aim,” “seek,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “forecast,” “potential” or “continue” or the negative of these terms or other similar expressions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition, and results of operations. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond our control. Factors that may cause actual results to differ materially from current expectations include, but are not limited to: competition; our ability to secure new (and retain existing) grant funding; our ability to grow and manage growth, maintain relationships with suppliers and retain our management and key employees; our ability to successfully advance our current and future product candidates through development activities, preclinical studies and clinical trials and costs related thereto; uncertainties inherent in the results of preliminary data and pre-clinical studies being predictive of the results of clinical trials; the timing, scope and likelihood of regulatory filings and approvals, including regulatory approval of our product candidates; changes in applicable laws or regulations; the possibility that the we may be adversely affected by other economic, business or competitive factors, including ongoing economic uncertainty; our estimates of expenses and profitability; the evolution of the markets in which we compete; our ability to implement our strategic initiatives and continue to innovate our existing products; our ability to defend our intellectual property; the impact of the ongoing COVID-19 pandemic on our business, supply chain and labor force; and the risks and uncertainties described in the “Risk Factors” section of our annual and quarterly reports filed the Securities Exchange Commission. These risks are not exhaustive and we face both known and unknown risks. You should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur, and actual results could differ materially from those projected in the forward-looking statements. Moreover, we operate in a dynamic industry and economy. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties that we may face. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

Contact Information:
Cognition Therapeutics, Inc.
info@cogrx.com

Aline Sherwood (media)
Scienta Communications
asherwood@scientapr.com

Daniel Kontoh-Boateng (investors)
Tiberend Strategic Advisors, Inc.
dboateng@tiberend.com 

FAQ

What are the key results from Cognition Therapeutics' recent studies on CT1812?

The studies identified biomarkers of CT1812 activity that replicated across the SHINE and SPARC trials, informing understanding of Alzheimer's disease progression.

When will Cognition Therapeutics present their findings?

Findings will be presented at the AD/PD™ 2023 conference held from March 28 to April 1, 2023.

What is the significance of the biomarkers identified in the analysis?

The biomarkers highlight the activity of CT1812 and its potential impact on various biological pathways associated with Alzheimer's disease.

What is CT1812 and what is its purpose?

CT1812 is an experimental treatment designed to penetrate the blood-brain barrier and target sigma-2 receptors, which are involved in cellular processes impacted by Alzheimer's disease.

Who will represent Cognition Therapeutics at the Alzheimer's Drug Discovery Foundation event?

CEO Lisa Ricciardi will participate in the panel discussion on March 29, focusing on novel approaches to treating Alzheimer's disease.